Posters

Modified corneal incision in cataract surgery in patients taking tamsulosin

Poster Details

First Author: M. Blau-Most ISRAEL

Co Author(s):    N. Gefen   O. Segal   E. Assia   F. Segev           

Abstract Details

Purpose:

Intraoperative floppy iris syndrome (IFIS) caused by systemic α blockers has been associated with an increased risk of cataract surgical complications. In this study we evaluate a simple technique, which involves modified anterior elongated corneal incisions, in order to reduce the incidence and severity of IFIS and related complications in patients taking tamsulosin (α blocker).

Setting:

Meir Medical Center, Kfar-Sava, Israel.

Methods:

A total of 45 eyes of 40 male patients taking tamsulosin, and thus prone to IFIS, were prospectively enrolled in this study between 08/2010 and 12/2015. They underwent phacoemulsification cataract surgery performed by a single surgeon, with elongated corneal incisions approximately 1 mm anterior to the limbus. The tamsulosin treatment period, IFIS development, IFIS severity (no IFIS, mild, moderate, severe), use of other IFIS management strategies, pupil dilatation during five stages of the surgery, complications and K readings before and after the surgeries were noted.

Results:

The overall rate of IFIS was 33.33% (n=15). The IFIS severity was rated as mild in 22.22% and moderate in 11.11% of the study eyes. No IFIS was noted in 66.67% of the eyes. There were no cases of severe IFIS. There was no need for other IFIS management strategies. The complications rate was 2.22% (n=1). We found a statistical correlation between IFIS development and pupil size in each of the five different stages of the surgery (t test, p<0.05), and no correlation between IFIS development and the tamsulosin treatment period (t test, p=0.19).

Conclusions:

Using our IFIS surgical technique reduces the incidence and severity of IFIS and allows a low complications rate during cataract surgery. Furthermore, there is a significant correlation between pupil size and risk of IFIS development.

Financial Disclosure:

NONE